Ключевые слова
Аннотация
Prostate cancer remains one of the most common malignancies affecting men worldwide and represents a significant public health challenge. Although advances in diagnostic technologies and therapeutic strategies have improved survival rates, prevention and early detection continue to play a crucial role in reducing morbidity and mortality associated with the disease. The multifactorial etiology of prostate cancer includes genetic predisposition, environmental influences, hormonal factors, lifestyle behaviors, and aging. Understanding these risk factors enables clinicians and public health professionals to implement targeted prevention strategies.
Screening modalities such as prostate-specific antigen (PSA) testing, digital rectal examination (DRE), and multiparametric magnetic resonance imaging (mpMRI) have transformed early detection practices. However, controversies regarding overdiagnosis and overtreatment highlight the need for risk-adapted screening approaches. This article reviews current evidence on prostate cancer prevention, modifiable risk factors, screening methods, emerging biomarkers, and public health strategies aimed at improving early diagnosis.
Библиографические ссылки
Siegel, R. L., Miller, K. D., & Jemal, A. Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 2023, pp. 17–48.
Rawla, P. Epidemiology of Prostate Cancer. World Journal of Oncology, 10(2), 2019, pp. 63–89.
Bray, F., Ferlay, J., Soerjomataram, I., et al. Global Cancer Statistics 2018: GLOBOCAN Estimates. CA: A Cancer Journal for Clinicians, 68(6), 2018, pp. 394–424.
Mottet, N., van den Bergh, R., Briers, E., et al. EAU Guidelines on Prostate Cancer. European Association of Urology, 2022, pp. 45–112.
American Cancer Society. Prostate Cancer Facts & Figures 2023–2024. Atlanta: ACS, 2023, pp. 1–36.
Carter, B. S., Beaty, T. H., Steinberg, G. D., et al. Mendelian Inheritance of Familial Prostate Cancer. The Journal of Urology, 150(3), 1993, pp. 797–802.
Pritchard, C. C., Mateo, J., Walsh, M. F., et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 375, 2016, pp. 443–453.
Rebbeck, T. R. Prostate Cancer Disparities by Race and Ethnicity. Nature Reviews Cancer, 18(2), 2018, pp. 79–92.
Feldman, B. J., & Feldman, D. The Development of Androgen-Independent Prostate Cancer. Nature Reviews Cancer, 1, 2001, pp. 34–45.
Freedland, S. J., & Platz, E. A. Obesity and Prostate Cancer: Making Sense out of Apparently Conflicting Data. Nature Clinical Practice Urology, 4(8), 2007, pp. 415–425.
World Cancer Research Fund / American Institute for Cancer Research. Diet, Nutrition, Physical Activity and Prostate Cancer. Continuous Update Project Expert Report, 2018, pp. 5–30.
Giovannucci, E. Tomatoes, Tomato-Based Products, Lycopene, and Cancer: Review of the Epidemiologic Literature. Journal of the National Cancer Institute, 91(4), 1999, pp. 317–331.
Kenfield, S. A., Stampfer, M. J., Giovannucci, E., et al. Physical Activity and Survival After Prostate Cancer Diagnosis. Journal of Clinical Oncology, 29(6), 2011, pp. 726–732.
Islami, F., Moreira, D. M., Boffetta, P., et al. A Systematic Review and Meta-Analysis of Tobacco Use and Prostate Cancer Mortality. European Urology, 72(5), 2017, pp. 712–719.
Thompson, I. M., Goodman, P. J., Tangen, C. M., et al. The Influence of Finasteride on the Development of Prostate Cancer. New England Journal of Medicine, 349, 2003, pp. 215–224.
Nelson, W. G., De Marzo, A. M., & Isaacs, W. B. Prostate Cancer. New England Journal of Medicine, 349, 2003, pp. 366–381.
Klein, E. A., Thompson, I. M., Tangen, C. M., et al. Vitamin E and the Risk of Prostate Cancer (SELECT Trial). JAMA, 306(14), 2011, pp. 1549–1556.
Schröder, F. H., Hugosson, J., Roobol, M. J., et al. Screening and Prostate Cancer Mortality: Results of the ERSPC Trial. New England Journal of Medicine, 360, 2009, pp. 1320–1328.
US Preventive Services Task Force. Screening for Prostate Cancer: Recommendation Statement. JAMA, 319(18), 2018, pp. 1901–1913.
Catalona, W. J., Richie, J. P., Ahmann, F. R., et al. Comparison of Digital Rectal Examination and Serum PSA. Urology, 38(6), 1991, pp. 557–561.
Ahmed, H. U., El-Shater Bosaily, A., Brown, L. C., et al. Diagnostic Accuracy of Multi-parametric MRI and TRUS Biopsy (PROMIS Study). The Lancet, 389(10071), 2017, pp. 815–822.
Deras, I. L., Aubin, S. M., Blase, A., et al. PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome. Clinical Chemistry, 54(6), 2008, pp. 1087–1093.
Klotz, L. Active Surveillance for Low-Risk Prostate Cancer. Current Urology Reports, 16(3), 2015, pp. 24–30.